Search
DG041
go.drugbank.com/drugs/DB05027ExperimentalDG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications. DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of th...
AN0128
go.drugbank.com/drugs/DB05054InvestigationalOf particular importance is P. acnes and its causal role in acne vulgaris. The rise in antibiotic resistance of P. acnes to standard antibiotics necessitates the development of new treatment agents.
AV608
go.drugbank.com/drugs/DB05072InvestigationalAV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).
NN344
go.drugbank.com/drugs/DB05115ExperimentalNN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile. The product is intended for basal insulin treatment of diabetes mellitus.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersPradefovir mesylate
go.drugbank.com/drugs/DB05478InvestigationalPradefovir is activated through oxidation that is mediated by cytochrome P-450 (CYP) 3A4, which is predominantly expressed in the liver.
SN-38
go.drugbank.com/drugs/DB05482Investigational7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan DB00762, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studyin...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsTechnetium Tc-99m ciprofloxacin
go.drugbank.com/drugs/DB05488Experimental99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis, wound infection, abdominal absce...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors(R)-warfarin
go.drugbank.com/drugs/DB08496ExperimentalWarfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways. S-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesTranilast
go.drugbank.com/drugs/DB07615InvestigationalTranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesQuinoline
go.drugbank.com/drugs/DB18050InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 Substrates